Fintel reports that on January 10, 2025, Piper Sandler initiated coverage of ResMed (NYSE:RMD) with a Neutral recommendation.

Michael Kantrowitz, Piper Sandler chief investment strategist, joins 'The Exchange' to discuss why higher rates pose the biggest risks to markets and more.

Piper Sandler raised the firm’s price target on Arhaus (ARHS) to $15 from $14 and keeps an Overweight rating on the shares ...

On Monday, Jan. 7, Michael Lavery at Piper Sandler initiated coverage of the beverage giant, with an overweight rating and a ...

Piper Sandler Companies is gaining traction with a recovering market. Find out why PIPR stock is becoming an attractive ...

Piper Sandler upgraded Par Pacific (PARR) to Overweight from Neutral with a price target of $25, up from $23. The company’s ...

Piper Sandler dipped into the beverage sector on Tuesday by issuing new Overweight ratings on Coca-Cola ( NYSE: KO) and ...

Piper Sandler upgraded Arthur J. Gallagher (AJG) to Overweight from Neutral with a price target of $315, up from $285. The firm believes ...

As previously reported, Piper Sandler upgraded Fortinet (FTNT) to Overweight from Neutral with a price target of $120, up from $100. The firm’s ...

Piper Sandler Companies (NYSE:PIPR – Get Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Tuesday.

Despite recent share appreciation, Piper Sandler believes there is still significant upside for Kenvue. “Though shares have ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...